Signals of bleeding among direct-acting oral anticoagulant users compared to those among warfarin users: analyses of the post-marketing FDA Adverse Event Reporting System (FAERS) database, 2010–2015

References

• KirchhofPBenussiSKotechaD2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTSEur Heart J201637382893296227567408
   PubMed Web of Science ®Google Scholar
• HartRGPearceLAAguilarMIMeta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillationAnn Intern Med20071461285786717577005
   PubMed Web of Science ®Google Scholar
• CooperNJSuttonAJLuGKhuntiKMixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillationArch Intern Med2006166121269127516801509
   PubMedGoogle Scholar
• JanuaryCTWannLSAlpertJS2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm SocietyJ Am Coll Cardiol20146421e1e7624685669
   PubMed Web of Science ®Google Scholar
• AnsellJHirshJHylekEJacobsonACrowtherMPalaretiGPharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th edChest20081336 Suppl160S198S18574265
   PubMed Web of Science ®Google Scholar
• MuellerRLScheidtSHistory of drugs for thrombotic disease. Discovery, development, and directions for the futureCirculation19948914324498281678
   PubMed Web of Science ®Google Scholar
• WarfarinDrugs@FDA. Food and Drug Administration [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009218s118lbl.pdfAccessed February 5, 2018
   Google Scholar
• WarfarinElectronic Medicines Compendium [Internet]. Available from: https://www.medicines.org.uk/emc/product/2803Accessed Febuary 5, 2018
   Google Scholar
• AnsellJHirshJPollerLBusseyHJacobsonAHylekEThe pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyChest20041263 Suppl204S233S15383473
   PubMed Web of Science ®Google Scholar
• BoulangerLKimJFriedmanMHauchOFosterTMenzinJPatterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practiceInt J Clin Pract200660325826416494639
   PubMed Web of Science ®Google Scholar
• PirmohamedMWarfarin: almost 60 years old and still causing problemsBr J Clin Pharmacol200662550951117061959
   PubMed Web of Science ®Google Scholar
• KimmelSEWarfarin therapy: in need of improvement after all these yearsExpert Opin Pharmacother20089567768618345947
   PubMed Web of Science ®Google Scholar
• HughesBFirst oral warfarin alternative approved in the USNat Rev Drug Discov201091290390621030985
   PubMed Web of Science ®Google Scholar
• KearonCAklEAOrnelasJAntithrombotic therapy for VTE disease: CHEST guideline and expert panel reportChest2016149231535226867832
   PubMed Web of Science ®Google Scholar
• WallentinLYusufSEzekowitzMDEfficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trialLancet2010376974597598320801496
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med2009361121139115119717844
   PubMed Web of Science ®Google Scholar
• DienerHCConnollySJEzekowitzMDDabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trialLancet Neurol20109121157116321059484
   PubMed Web of Science ®Google Scholar
• Dabigatran. Drugs@FDAFood and Drug Administration Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022512s028lbl.pdfAccessed February 5, 2018
   Google Scholar
• Food and Drug AdministrationDrugs@FDA: FDA Approved Drug Products Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022406Accessed January 15, 2018
   Google Scholar
• PatelMRMahaffeyKWGargJRivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med20113651088389121830957
   PubMed Web of Science ®Google Scholar
• Rivaroxaban. Drugs@FDAFood and Drug Administration Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202439s001lbl.pdfAccessed February 3, 2017
   Google Scholar
• Gomez-OutesATerleira-FernandezAICalvo-RojasGSuárez-GeaMLVargas-CastrillónEDabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroupsThrombosis2013201364072324455237
   PubMedGoogle Scholar
• PoliDAntonucciETestaSBleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for AnticoagulationCirculation2011124782482921810658
   PubMed Web of Science ®Google Scholar
• Food and Drug AdministrationPost-Marketing Surveillance Programs [updated 2014 Aug 19] Available from: https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/surveillance/ucm090385.htmAccessed January 15, 2018
   Google Scholar
• Food and Drug Administration Available from: https://open.fda.gov/data/faers/Accessed January 7, 2018
   Google Scholar
• The FDA Adverse Event Reporting System (FAERS)Food and Drug Administration (FDA) Available from: https://www.fda.gov/DrugsGuidanceComplianceRegulatoryInformation/Surveillance/Adverse-DrugEffects/Accessed December 13, 2017
   Google Scholar
• OpenFDAThe FDA Adverse Event Reporting System (FAERS)Food and Drug Administration (FDA) Available from: https://open.fda.gov/data/faers/Accessed December 13, 2017
   Google Scholar
• SakaedaTTamonAKadoyamaKOkunoYData mining of the public version of the FDA Adverse Event Reporting SystemInt J Med Sci201310779680323794943
   PubMed Web of Science ®Google Scholar
• BöhmRReporting odds ratio. primer on disproportionality analysis2015 Available from: http://openvigil.sourceforge.net/doc/DPA.pdfAccessed February 2, 2018
   Google Scholar
• WaningBMontagneMPharmacoepidemiology Principles and Practice Chapter 8: Post-marketing surveillanceNew YorkMcGraw Hill Education2001
   Google Scholar
• BaiYDengHShantsilaALipGYRivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysisStroke201748497097628213573
   PubMed Web of Science ®Google Scholar
• HolsterILValkhoffVEKuipersEJTjwaETNew oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysisGastroenterology20131451105.e15112.e1523470618
   PubMed Web of Science ®Google Scholar
• GrahamDJReichmanMEWerneckeMStroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillationJAMA Intern Med2016176111662167127695821
   PubMed Web of Science ®Google Scholar
• ChenEYDiugBBellJSSpontaneously reported haemorrhagic adverse events associated with rivaroxaban and dabigatran in AustraliaTher Adv Drug Saf20167141026834958
   PubMedGoogle Scholar
• BytzerPConnollySJYangSAnalysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trialClin Gastroenterol Hepatol2013113246252e1523103906
   PubMed Web of Science ®Google Scholar
• SouthworthMRReichmanMEUngerEFDabigatran and postmarketing reports of bleedingN Engl J Med2013368141272127423484796
   PubMed Web of Science ®Google Scholar
• AbrahamNSSinghSAlexanderGCComparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort studyBMJ2015350h185725910928
   PubMed Web of Science ®Google Scholar
• ChughSSHavmoellerRNarayananKWorldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 StudyCirculation2014129883784724345399
   PubMed Web of Science ®Google Scholar
• StaerkLFosbølELGadsbøllKNon-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011–2015 in DenmarkSci Rep201663147727510920
   PubMed Web of Science ®Google Scholar
• MedWatcher Available from: https://medwatcher.org/Accessed February 7, 2017
   Google Scholar
• EdwardsRLindquistMPharmacovigilance: Critique and Ways ForwardNew YorkSpringer2017
   Google Scholar
• SchulmanSKearonCKakkarAKExtended use of dabigatran, warfarin, or placebo in venous thromboembolismN Engl J Med2013368870971823425163
   PubMed Web of Science ®Google Scholar
• ErikssonBIBorrisLCFriedmanRJRivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplastyN Engl J Med2008358262765277518579811
   PubMed Web of Science ®Google Scholar
• ErikssonBIDahlOERosencherNOral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: pooled analysis of two phase 3 randomized trialsThromb J2015133626578849
   PubMedGoogle Scholar
• SchulmanSKearonCKakkarAKDabigatran versus warfarin in the treatment of acute venous thromboembolismN Engl J Med2009361242342235219966341
   PubMed Web of Science ®Google Scholar
• ErikssonBIDahlOERosencherNOral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trialJ Thromb and Haemost20075112178218517764540
   PubMed Web of Science ®Google Scholar
• GinsbergJSDavidsonBLCompPCOral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgeryJ Arthroplasty200924119
   PubMed Web of Science ®Google Scholar